Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2019

View Archived Issues

New model explains neural basis of alternating bilateral sensory stimulation for fear disorders

Stress hormones help metastasis along

How the other half controls appetite

Clotting protein cuts neuromuscular synapses, if it can

SunRegen Healthcare presents data on SRG-003 in monkeys with optic atrophy

Preclinical PK/PD studies help determine first-in-human dose of RG-7827

JP-1366 demonstrates safety and favorable PK in healthy subjects

FDA approves sNDA for Avycaz for pediatric patients with cUTI and cIAI

FDA clears Zenith Epigenetics' IND application for ZEN-3694 in TNBC program

Idorsia patents antibacterial pyrroloimidazolones

Novartis patent describes compounds for cancer

Asceneuron discloses OGA inhibitors

Sprint Bioscience synthesizes PIK3C3 inhibitors

TIME-2b study of AKB-9778 in diabetic retinopathy does not meet primary endpoint

ACADIA Pharmaceuticals presents 5-HT2A receptor ligands

Pascal Biosciences and Mitacs partner to support cancer research project at UBC

FDA approves Tecentriq with chemotherapy for first-line treatment of extensive-stage SCLC

Clinical data reported for litoxetine in mixed urinary incontinence

First subject dosed in phase II study of GRF-6019 in patients with severe Alzheimer's disease

Nicox opens phase II trial of NCX-4251 in blepharitis

NAMPT might predict docetaxel resistance in prostate cancer

First-in-human results for miltuximab described, theranostic trial of 89Zr/177Lu-miltuximab planned

Emergent BioSolutions initiates phase III study of anthrax vaccine AV-7909

Moleculin Biotech enrolls first patients in European trial of WP-1220 for CTCL

Crinetics initiates phase II program for CRN-00808 in acromegaly

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...